期刊文献+

河北省预防接种异常反应商业保险补偿模式的公众态度分析 被引量:7

Public attitudes toward insurance-based compensation for adverse reactions following immunization in Hebei province
原文传递
导出
摘要 目的了解公众对河北省引入预防接种异常反应保险补偿模式的看法,为推进实施保险补偿模式提供参考依据。方法对卫生行政人员、疾病控制人员、接种医生、儿童家长共计540人进行问卷调查,对调查数据进行描述性分析。结果在537名有效调查对象中,30%清楚现行的河北省预防接种异常反应补偿办法;52%不满意该补偿办法,主要是因为补偿金额低、补偿时限过长等;77%认为商业保险补偿模式可行;87%愿意为孩子额外购买该类保险。结论公众赞成实施预防接种异常反应保险补偿模式,并愿意额外购买保险产品。 Objective To assess public attitudes to the introduction of insurance for compensating adverse reactions following immunization (ARFI) in Hebei, and to provide evidence for promoting insurance- based compensation. Methods A questionnaire was used to survey 540 subjects that included health administrative staff, disease control staff, immunization doctors, and children's parents. Data were ana- lyzed by descriptive methods. Results Among 537 respondents with valid, completed questionnaires, 74% knew the current Hebei ARFI compensation method; 52% were not satisfied with the compensation method due to 'low compensation fees and long compensation time; 77% believed that commercial insur- ance for compensation was feasible; 87% would like to buy compensation insurance for their children. Conclusion The Hebei public accepts insurance-based ARFI compensation and is willing to buy addi- tional insurance products.
出处 《中国疫苗和免疫》 北大核心 2017年第3期278-281,共4页 Chinese Journal of Vaccines and Immunization
基金 联合国儿童基金会(项目编号:EPI RWP 2014 1.4)
关键词 预防接种异常反应 保险 补偿 态度 Adverse reaction following immunization Insurance Compensation Attitude
  • 相关文献

参考文献5

二级参考文献51

  • 1留岚兰.浅谈培训效果的评估[J].技术经济与管理研究,2004(5):54-54. 被引量:31
  • 2谢广中.预防接种后不良反应分类之我见[J].中国计划免疫,2004,10(5):313-315. 被引量:13
  • 3卫生部.预防接种工作规范[S],2005-09-20.
  • 4卫生部办公厅,国家食品药品监督管理局办公室.全国疑似预防接种异常反应监测方案[S].2010-06-03.
  • 5WHO & WPRO. Immunization Safety Surveillance[M].Manila,Phillipines,1999.5~13.
  • 6PAHO.Guidelines for Managing Immunization Safety Concerns[M].Washington D C, United States, 2002.4.
  • 7Robert T Chen. AEFI Surveillance Systems in other Countries[R]. Beijing, China,2003.
  • 8Kari S Lankinen, Satu Pastila, Terhi Kilpi, et al. Vaccinovigilance in Europe-need for timeliness, standardization and resources[J]. Bull WHO.2004,82:828-835.
  • 9William L Atkinson, Charles (Skip) Wolfe. Epidemiology and Prevention of Vaccine Preventale Diseases Seventh Edition[M].2002.221-222.
  • 10Collet J P, MacDonald N, Cashman N, et al. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee[J]. Bull WHO, 2000,78:178-185.

共引文献339

同被引文献56

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部